Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on April 20, 2020, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising mechanism.
- Previous Offering Capacity: $25 million aggregate offering price under the original Sale Agreement.
- Shares Sold to Date: Approximately $21 million aggregate offering price sold as of April 20, 2020.
- New Offering Capacity: An additional $25 million aggregate offering price authorized under the Amended Sale Agreement.
- Agent Commission: Up to 3.0% of gross proceeds from future sales.
Material Changes
On April 20, 2020, the Company amended its Open Market Sale Agreement with Jefferies LLC and B. Riley FBR, Inc. The amendment increases the aggregate offering amount available for sale by an additional $25 million. Prior to this amendment, the Company had already sold approximately $21 million of the original $25 million authorization.
Guidance, Outlook, and Risks
Management Commentary: The Company may offer and sell shares from time to time based on its instructions, including price, time, or size limits. The offering will terminate upon the sale of the maximum permitted shares or earlier termination by the parties.
Risks and Contingencies: The Company explicitly states it cannot provide assurances that it will issue any additional shares pursuant to the Amended Sale Agreement. Sales are subject to market conditions and the Company's discretion.
Investor Verification Checklist
- Verify the total number of shares outstanding and the potential dilution impact of selling an additional $25 million of stock.
- Review the attached Amendment (Exhibit 1.1) for specific terms regarding price floors or sales restrictions.
- Monitor future filings to track the actual volume of shares sold under the new authorization.
- Confirm the current cash position in the most recent 10-Q or 10-K to understand the urgency of this capital raise.